MultiValent Biotherapies
PrivateLast Round
Series A
Jun 16, 2026
Total Funding Raised
$27.43M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
MultiValent Biotherapies, Inc. is a biotechnology company developing targeted drug conjugate therapies for cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MultiValent Biotherapies Comparables
Compare MultiValent Biotherapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coherent Biopharma | 83% | |
| Tianjin Conjustar Biotechnology Co., Ltd. | 78% | |
| Eli Lilly and Company | 77% | |
MultiValent Biotherapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 16, 2026 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2026
$27M round led by Coherent Biopharma
MultiValent Biotherapies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MultiValent Biotherapies's valuation, stock price, and market status.